Capellà D, Torres F, Avila P, Moreno V, Laporte J R
Centro Coordinador del Sistema Español de Farmacovigilancia, Universidad Autónoma de Barcelona.
Med Clin (Barc). 1991 Feb 2;96(4):126-8.
Cough is one of the possible untoward adverse drug effects of angiotensin converting enzyme inhibitors. We describe the available information on 50 cough episodes attributable to captopril and 18 episodes attributable to enalapril reported to the Spanish Drug Surveillance System. Cough represented 37% and 39% of the reports of side effects of captopril and enalapril, respectively. There was a remarkable female predominance among the patients with cough. Cough developed at very low doses (15 mg of captopril and 5 mg of enalapril daily), although the patients on captopril who developed cough were receiving higher doses than those who presented other side effects. A high proportion of patients (29%) continued with the drug for more than six months after cough had developed, suggesting the need for a wider knowledge of this side effect.
咳嗽是血管紧张素转换酶抑制剂可能产生的不良药物作用之一。我们描述了向西班牙药物监测系统报告的50例因卡托普利引起的咳嗽发作和18例因依那普利引起的咳嗽发作的现有信息。咳嗽分别占卡托普利和依那普利副作用报告的37%和39%。咳嗽患者中女性占比显著。咳嗽在非常低的剂量下(卡托普利每日15毫克和依那普利每日5毫克)就会出现,尽管出现咳嗽的卡托普利患者所接受的剂量高于出现其他副作用的患者。很大一部分患者(29%)在咳嗽出现后继续用药超过六个月,这表明需要更广泛地了解这种副作用。